Gestational diabetes secondary prevention

Diabetes mellitus main page
Gestational diabetes Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Gestational Diabetes from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History and Prognosis
Complications Maternal Fetal and Neonatal
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Dietary Therapy
Medical Therapy
Primary Prevention
Secondary Prevention
Surgery
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Gestational diabetes secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Gestational diabetes secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Gestational diabetes secondary prevention
CDC on Gestational diabetes secondary prevention
Gestational diabetes secondary prevention in the news
Blogs on Gestational diabetes secondary prevention
Directions to Hospitals Treating Gestational diabetes
Risk calculators and risk factors for Gestational diabetes secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]

Overview

After delivery, mothers who diagnosed with GDM, should have close follow up to prevent overt diabetes in future. Testing with 75 g OGTT 6 to 12 weeks after delivery and then every 1-3 years is recommended for early diagnosis.

Secondary Prevention

• The OGTT is recommended over A1C at the 6 to 12 week postpartum visit because A1C may be persistently impacted (lowered) by the increased red blood cell turnover related to pregnancy or blood loss at delivery.
• Because GDM is associated with increased maternal risk for diabetes, women should also be tested every 1–3 years thereafter if 6 to 12 week 75-g OGTT is normal, with frequency of screening depending on other risk factors including family history, prepregnancy BMI and need for insulin or oral glucose lowering medication during pregnancy.
• Ongoing screening may be performed with any recommended glycemic test (e.g., hemoglobin A1C, fasting plasma glucose, or 75-g OGTT using nonpregnant thresholds).